Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a chimeric (human-murine) IgG1 kappa monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody binds to and neutralizes human IL-6, inhibits IL-6 binding to its receptor, and subsequent IL-6 signaling. The original monoclonal antibody received FDA approval to treat patients suffering from multicentric Castlemans disease and negative for HIV and HHV-8. This monoclonal antibody has recently been investigated for the treatment of various forms of cancer such as metastatic renal cell cancer, ovarian cancer, and prostate cancer.
Biovision | A2143 | Anti-IL-6 (Siltuximab), Chimeric Antibody DataSheet
Antibody Target: IL-6
Target Alternative Name: CDF, HGF, HSF, BSF2, IL-6, BSF-2, IFNB2, IFN-beta-2, IL6
Tag Line: A chimeric monoclonal antibody that targets and prevents the binding of human IL-6 with its receptors, which results in decreased lymphocyte proliferation
Category: Biosimilars
Host: Human/Mouse chimeric
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Siltuximab
Accession #: DB09036
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
